News

Florin Despa presents at Duke University & University of Kentucky Grand Rounds

Apr 28, 2023

This year, Dr. Florin Despa, Ph.D., has presented twice to medical residents in Grand Rounds presentations. Dr. Despa presented locally at the University of Kentucky College of Medicine Pathology Grand Rounds on January 20th, 2023. His presentation was entitled "Systemic inflammation and impairment of cerebral Aβ clearance provoked by pancreatic amyloid-forming amylin."

Despa Lab Publication is a Top Cited Article, Receives Press Attention

Feb 21, 2023

This morning, the Despa Lab received notification that our paper suggesting that modulation of blood amylin levels may impact Alzheimer's disease pathology (linked here) is among the journal Alzheimer's & Dementia: Translational Research & Clinical Interventions top cited papers!

Florin Despa speaks at the Clinical Trials on Alzheimer's Disease Congress 2022

Nov 28, 2022

Dr. Florin Despa, Ph.D., provided attendees of the Clinical Trials on Alzheimer's Disease Congress 2022 in San Francisco with several interviews as well as a talk, wherein he discusses the lab's ongoing work to understand the role of amyloidogenic amylin in Alzheimer's disease and associated cognitive decline. His talk was entitled "Systemic inflammation and reduced cerebral Aβ clearance triggered by pancreatic amylin."

Florin Despa speaks in Seoul on the effect of amylin downregulation on glucose homeostasis

Oct 16, 2022

Dr. Florin Despa, Ph.D., presented work from the Despa Lab in Seoul, South Korea this week. His talk was entitled "In vivo downregulation of pancreatic amylin in diabetic mice improves systemic and central glucose homeostasis." His presentation was part of the 2022 Society for Heart and Vascular Metabolism Conference.

Florin Despa Presents at ADPD 2022, Interviews Available On-Demand

Mar 16, 2022

While attending the Alzheimer's Disease / Parkinson's Disease (AD/PD) 2022 Conference in Barcelona, Spain, Dr. Florin Despa gave a talk on our lab's work, which was entitled "The hypothesis of diabetes-associated cerebrovascular amylin deposits blocking β amyloid elimination from the Alzheimer’s disease brain." Dr. Despa was also interviewed on what could underlie the increased risk of individuals with type-2 diabetes developing dementia. In another interview, he also discusses how hyperamylinemia impairs Aβ removal in the brains of individuals with Alzheimer's disease.